What makes this different from a standard hip injection

Most hip injections patients encounter — corticosteroids for inflammation, hyaluronic acid for lubrication — work at the symptom level. They do not deposit any structural material for the joint to build on, and they leave the underlying cartilage defect unchanged.

ChondroFiller® liquid is built on a different principle. It is an acellular Type I collagen hydrogel that self-gels within minutes of injection, forming a three-dimensional scaffold inside the cartilage defect. That scaffold is not a passive filler sitting in the space; it is a biological template the body's own chondrocytes and progenitor cells can migrate into, using it as a framework to lay down new tissue. This places it in a distinct regenerative scaffold category — not a pain-modifying injection, not a lubricant, and not a surgical implant.

The treatment is delivered as an outpatient procedure under ultrasound guidance, with no operating theatre, no general anaesthetic, and no hospital stay. The sections below explore how the scaffold behaves inside the hip joint, why ultrasound guidance is essential at this anatomical site, which patients are most likely to benefit, and what the published evidence currently shows.

How the collagen scaffold works inside the hip joint

Think of the scaffold as a temporary framework — a structural invitation that signals to nearby repair cells: here is a place to build. Once the collagen solution contacts the synovial fluid environment of the defect, it polymerises and stabilises into a porous three-dimensional matrix within minutes.

The body then does the work. Chondrocytes and progenitor cells from the surrounding tissue migrate into that matrix; ChondroFiller® contributes no donor cells of its own. A 2025 ex vivo human osteochondral study measured a 2.4-fold increase in DNA content within the scaffold by day 14 — laboratory-level confirmation that this cell recruitment does occur. That figure reflects biological activity in a tissue model, not a clinical outcome.

Over the following weeks and months, the recruited cells begin depositing repair tissue within the matrix. As endogenous tissue consolidates, the collagen scaffold gradually biodegrades, leaving the newly formed material in its place rather than a permanent foreign body.

Two practical consequences follow directly from this biology. First, the scaffold remains mechanically vulnerable in the early post-procedure window — a biomechanical in-vitro study found it cannot protect opposing cartilage from load until stable integration has been achieved, which is why the weight-bearing period after treatment requires careful management. Second, overfilling a defect is associated with fibrous tissue formation rather than the hyaline-type repair that is the treatment's aim. Precise volume dosing — typically only a small fraction of the 1 mL preparation — is therefore important to the quality of the eventual result.

Why ultrasound guidance is essential for hip injection

The hip's anterior anatomy creates a safety case for image guidance that surface-landmark techniques cannot meet. Three major structures run in close proximity to the standard anterior needle path: the femoral artery lies approximately 1.9 cm medial to the capsule, the femoral vein approximately 1.7 cm medial, and the femoral nerve approximately 2.3 cm lateral. Compounding this, the lateral circumflex femoral artery courses over the anterior capsule at a position that varies between patients — one that cannot be predicted from external landmarks alone, regardless of clinical experience.

The consequence of working without image guidance is measurable. A 2016 systematic review by Hoeber et al. found that landmark-guided hip injections achieve confirmed intra-articular placement in only 72% of cases (95% CI 56–85%). Image-guided techniques achieved 100% accuracy (95% CI 98–100%), a difference that reached statistical significance at p<0.0001. For a scaffold material that must be deposited precisely within the cartilage defect to activate repair, those placement rates are not interchangeable.

Real-time colour Doppler imaging addresses both problems simultaneously. It maps vascular structures before needle insertion and tracks the long spinal needle in-plane throughout its path, allowing the clinician to confirm that the tip is advancing safely lateral to the neurovascular bundle. Once the needle is seated in the anterior joint recess, the liquid collagen is deposited slowly into the synovial fluid environment, where it polymerises in situ within minutes. At no stage does the process rely on anatomical estimates that may not reflect an individual patient's anatomy — which is precisely the limitation that the Hoeber accuracy data exposes.

Which hip patients are most likely to benefit

Patient selection is where the available evidence draws its clearest lines.

The hip series published by Perez-Carro et al. in the Journal of Hip Preservation Surgery (2021) enrolled patients with femoroacetabular impingement and acetabular cartilage lesions measuring more than 2 cm² — a threshold that indicates this approach targets established, full-thickness focal damage rather than early-stage or superficial changes. Of the 21 patients available at three-to-five year follow-up, 17 achieved good or excellent MRI-confirmed results.

The single most important exclusion finding from that study concerns the degree of background joint degeneration. Patients with pre-existing widespread osteoarthritis — Tönnis grade 2 or 3 — had uniformly poor outcomes. Summarised plainly: a scaffold designed to fill a defined hole cannot reverse a joint that is broadly worn down. The indication sits firmly with focal, contained damage in an otherwise reasonably preserved joint — not with generalised joint degeneration.

Candidates most likely to fit the profile are those whose imaging shows a specific cartilage lesion, typically associated with impingement anatomy, rather than widespread joint narrowing. A clinical assessment will generally evaluate defect size and location, the degree of any surrounding degeneration, and whether structural factors contributing to the damage also need to be addressed.

ChondroFiller is not currently NHS-funded in the UK and follows a self-pay pathway. Establishing whether the clinical profile matches the indication is the appropriate first step.

What the clinical evidence currently shows

The Perez-Carro cohort covered in the previous section represents the only published hip-specific series to date — a meaningful anchor, but an early one. Evidence from adjacent joints fills in the mechanistic picture and, where it can, supports transferability.

Knee data: the strongest controlled evidence

A multicentre randomised controlled trial comparing ChondroFiller with microfracture — one of the most widely used surgical approaches for focal cartilage defects — reported statistically significant IKDC score improvements in the ChondroFiller group at 3, 6, and 12 months (p<0.05). MRI confirmed good defect filling and progressive cartilage maturation on MOCART scoring, and no adverse events were recorded. Across multiple knee studies synthesised in the April 2025 Clinical Evaluation Report, IKDC scores improved by approximately 30 points over 12 months — a clinically meaningful functional gain, though industry-collated data warrants the usual interpretive caution.

Cartilage quality findings from a 2025 wrist study

A 2025 study examining ChondroFiller in intra-articular distal radius fractures found significantly better cartilage quality at follow-up arthroscopy: median Outerbridge scores of 1.5 versus 3.0 (p=0.006) and ICRS scores of 1 versus 3 (p=0.002) in favour of the treated group. Wrist mechanics differ from the hip, but the histological signal adds a second joint to the cross-articular pattern.

An honest account of what remains unestablished

One distinction matters here: the Perez-Carro hip series used arthroscopic placement under surgical conditions, not ultrasound-guided outpatient injection. The mechanistic case for the injectable route is supported by the knee RCT data; direct randomised evidence for percutaneous hip injection specifically does not yet exist in the published literature. The directional consistency across knee, wrist, and hip cohort findings is encouraging — it is not the same as long-term, hip-specific injection trial data, which remains awaited.

What the appointment and recovery period involve

Recovery planning begins before the injection itself. The procedure is a single outpatient appointment under local anaesthetic — but the practical question patients most often raise is what the days and weeks that follow actually look like.

A 2024 biomechanical study established that ChondroFiller carries some initial mechanical instability before the scaffold achieves stable integration, meaning it cannot fully buffer the opposing cartilage surface under load during that earliest period. Activity modification — typically reduced weight-bearing and avoidance of high-impact movement in the early weeks — is therefore a clinically grounded requirement, not a generic precaution. The specific restrictions depend on defect size, location, and individual anatomy, and are confirmed at consultation rather than fixed as a universal rule.

Monitoring cartilage maturation

MRI is the standard tool for tracking repair progress over the months following injection. As the scaffold gradually biodegrades, follow-up imaging helps confirm whether organised repair tissue is developing appropriately and informs decisions about returning to more demanding activity.

ChondroFiller is not available through the NHS and is funded privately. Costs vary by clinical complexity and are best discussed directly at consultation. An online assessment at amsk.co.uk is the appropriate starting point for establishing individual suitability and obtaining a full cost outline.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing for focal knee cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z